Management of Fecal Peritonitis with Clostridium perfringens

Rationale for Clindamycin Addition

The American Society of Infectious Diseases recommends clindamycin (600-900 mg IV every 8 hours) as a first-line agent for Clostridium infections due to its superior coverage against clostridiales and essential anti-toxin properties to reduce morbidity and mortality 1, 2.
Clindamycin possesses toxin-suppressing properties crucial in C. perfringens infections, where toxins significantly contribute to morbidity, and it also modulates cytokine production, reducing systemic inflammatory response 3.

The Infectious Diseases Society of America notes that secondary fecal peritonitis is typically polymicrobial, involving 2-3 aerobic and 1-2 anaerobic species, including E. coli, Klebsiella spp., streptococci, Bacteroides fragilis, and potentially Clostridium perfringens 4, 5.
Inadequate antimicrobial therapy is associated with significantly higher mortality (42% vs 17.7%) in intra-abdominal infections, emphasizing the need for appropriate and early empirical broad-spectrum antibiotic therapy 2.

The optimal regimen for polymicrobial fecal peritonitis with C. perfringens combines ampicillin-sulbactam or piperacillin-tazobactam with clindamycin (600-900 mg IV every 8 hours) and ciprofloxacin or an aminoglycoside for coverage of resistant Gram-negative bacilli 3.
Carbapenems offer broad-spectrum coverage but may lack clindamycin's anti-toxin properties, justifying the addition of clindamycin for specific anti-toxin effects against C. perfringens 3.

The World Society of Emergency Surgery recommends that culture and antibiogram results should guide therapeutic adjustments once available, considering potential resistance to clindamycin among C. perfringens strains 4, 5.
Surgery and drainage remain cornerstones of treatment for intra-abdominal infections, directly impacting prognosis, and adequate source control is crucial as antibiotic therapy cannot compensate for inadequate source control 2.
The duration of antibiotic therapy should be shortened after resolution of physiological abnormalities in patients with adequate source control, with a fixed duration of 4 days showing similar results to prolonged treatment 6.
Prolonging antibiotics beyond 10 days increases the risk of colonization by resistant strains, including enterococci 7.